Literature DB >> 17425725

Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation.

Shigeru Marubashi1, Keizo Dono, Hiroaki Nagano, Yukari Sugita, Tadafumi Asaoka, Naoki Hama, Atsushi Miyamoto, Yutaka Takeda, Koji Umeshita, Morito Monden.   

Abstract

The aim of this study was to evaluate the hypothesis that the detection of alpha-fetoprotein (AFP) mRNA-expressing cells could be a novel, direct and accurate method for predicting tumor recurrence after living donor liver transplantation (LDLT) in patients with hepatocellular carcinoma (HCC). The test group consisted of 32 patients who underwent LDLT for end-stage liver disease with HCC. Quantitative real-time reverse transcription polymerase chain reaction was used for the detection of AFP mRNA-expressing cells in the peripheral blood. Nine (28.1%) of the 32 patients developed tumor recurrences during the follow-up period (mean, 27.9 months). The test for the presence of AFP mRNA in the peripheral blood was positive either preoperatively or postoperatively in 11 (34.3%) of the 32 patients, and positive preoperatively in three patients (9.4%). Univariate analysis revealed that a positive preoperative test for peripheral blood AFP mRNA, as well as exceeding Milan criteria and microscopic evidence of vascular invasion were significant predictors for the recurrence of HCC (P = 0.002, 0.049, and 0.001, respectively). Multivariate analysis using Cox's proportional hazards model revealed that a positive preoperative test for peripheral blood AFP mRNA was an independent risk factor for the recurrence of HCC. We concluded that the presence of AFP mRNA-expressing cells preoperatively could be a useful predictor of the recurrence of HCC in liver transplant patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425725     DOI: 10.1111/j.1432-2277.2007.00480.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  13 in total

1.  The Clinical Significance of Alpha-Fetoprotein mRNAs in Patients with Hepatocellular Carcinoma.

Authors:  Shogo Kobayashi; Akira Tomokuni; Hidenori Takahashi; Hirofumi Akita; Keijiro Sugimura; Norikatsu Miyoshi; Jeong Ho Moon; Masayoshi Yasui; Takeshi Omori; Masayuki Ohue; Yoshiyuki Fujiwara; Masahiko Yano; Masato Sakon
Journal:  Gastrointest Tumors       Date:  2017-02-08

Review 2.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis.

Authors:  Hiroshi Wada; Hidetoshi Eguchi; Hiroaki Nagano; Shoji Kubo; Takuya Nakai; Masaki Kaibori; Michihiro Hayashi; Shigekazu Takemura; Shogo Tanaka; Yasuyuki Nakata; Kosuke Matsui; Morihiko Ishizaki; Fumitoshi Hirokawa; Koji Komeda; Kazuhisa Uchiyama; Masanori Kon; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2017-06-08       Impact factor: 2.549

4.  Effects of pre-operative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: Implication of circulating cancer cells by detection of α-fetoprotein mRNA.

Authors:  Masahiro Murakami; Hiroaki Nagano; Shogo Kobayashi; Hiroshi Wada; Masato Nakamura; Shigeru Marubashi; Hidetoshi Eguchi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

Review 5.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

6.  Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China.

Authors:  Jia Fan; Guang-Shun Yang; Zhi-Ren Fu; Zhi-Hai Peng; Qiang Xia; Chen-Hong Peng; Jian-Ming Qian; Jian Zhou; Yang Xu; Shuang-Jian Qiu; Lin Zhong; Guang-Wen Zhou; Jian-Jun Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-21       Impact factor: 4.553

7.  Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC.

Authors:  Yuliang Wang; Zhongyang Shen; Zhijun Zhu; Ruifa Han; Mingsheng Huai
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

8.  Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.

Authors:  Nan Zhang; Jiajia Gu; Li Yin; Jing Wu; Ming-Yu Du; Kai Ding; Teng Huang; Xia He
Journal:  Oncotarget       Date:  2016-12-06

9.  Independent risk factors for disease recurrence after surgery in patients with hepatitis B virus-related hepatocellular carcinoma ≤3 cm in diameter.

Authors:  Ling-Ling He; Xiao-Li Liu; Shuan Zhang; Meng-Ge Li; Xian-Bo Wang; Yu-Yong Jiang; Zhi-Yun Yang
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-03-30

Review 10.  Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Maria J Citores; Jose L Lucena; Sara de la Fuente; Valentin Cuervas-Mons
Journal:  World J Hepatol       Date:  2019-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.